A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs ALN TTRsc02 (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 10 Feb 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2018.
    • 10 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
    • 02 Nov 2016 Initial clinical results from this study will be presented at the R&D Day, according to an Alnylam Pharmaceuticals media release,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top